These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8112245)

  • 1. Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation.
    Schäffler L; Bourgeois BF; Lüders HO
    Epilepsia; 1994; 35(1):195-8. PubMed ID: 8112245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data.
    Battino D; Croci D; Rossini A; Messina S; Mamoli D; Perucca E
    Epilepsia; 2003 Jul; 44(7):923-9. PubMed ID: 12823575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC; Hoem NO; Glauser T; Vinks AA
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of free carbamazepine in adult Omani epileptic patients.
    Deleu D; Aarons L; Ahmed IA
    Eur J Clin Pharmacol; 2001 Jun; 57(3):243-8. PubMed ID: 11497340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid switchover to carbamazepine using pharmacokinetic parameters.
    Kanner AM; Bourgeois BF; Hasegawa H; Hutson P
    Epilepsia; 1998 Feb; 39(2):194-200. PubMed ID: 9578000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive study of the relation between serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites with age, weight, dose, and clearances in epileptic children.
    Liu H; Delgado MR
    Epilepsia; 1994; 35(6):1221-9. PubMed ID: 7988515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics: time-dependent changes--autoinduction of carbamazepine epoxidation.
    Bertilsson L; Tomson T; Tybring G
    J Clin Pharmacol; 1986; 26(6):459-62. PubMed ID: 3734137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Piperine on the Metabolism and Pharmacokinetics of Carbamazepine in Healthy Volunteers.
    Bedada SK; Appani R; Boga PK
    Drug Res (Stuttg); 2017 Jan; 67(1):46-51. PubMed ID: 27776366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
    Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
    Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism.
    Macphee GJ; Butler E; Brodie MJ
    Epilepsia; 1987; 28(3):286-94. PubMed ID: 3582293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early stage autoinduction of carbamazepine metabolism in humans.
    Bernus I; Dickinson RG; Hooper WD; Eadie MJ
    Eur J Clin Pharmacol; 1994; 47(4):355-60. PubMed ID: 7875188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased valproate serum concentrations upon carbamazepine cessation.
    Jann MW; Fidone GS; Israel MK; Bonadero P
    Epilepsia; 1988; 29(5):578-81. PubMed ID: 3137021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.
    Kudriakova TB; Sirota LA; Rozova GI; Gorkov VA
    Br J Clin Pharmacol; 1992 Jun; 33(6):611-5. PubMed ID: 1389933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
    Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
    Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy.
    Bonneton J; Iliadis A; Genton P; Dravet C; Viallat D; Mesdjian E
    Epilepsy Res; 1993 Mar; 14(3):257-63. PubMed ID: 8504796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.
    Spina E; Tomson T; Svensson JO; Faigle JW; Bertilsson L
    Ther Drug Monit; 1988; 10(4):382-5. PubMed ID: 3201523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique.
    Bertilsson L; Höjer B; Tybring G; Osterloh J; Rane A
    Clin Pharmacol Ther; 1980 Jan; 27(1):83-8. PubMed ID: 7351120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers.
    Bedada SK; Nearati P
    Phytother Res; 2015 May; 29(5):701-6. PubMed ID: 25624269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level/dose ratios of carbamazepine and its metabolites.
    Liu H; Delgado MR
    Ther Drug Monit; 1994 Oct; 16(5):469-76. PubMed ID: 7846744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.